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with and without abscopal responses was respectively of 22.4 
months (range 2,5-50,3) and 8,3 months (range 7,6-9.0). 11 
out of 13 patients with local response showed an abscopal 
effect. 
 
Conclusion: The RT after ipilimumab treatment may be an 
option for further potentiate its effect. Local response to RT 
might be predictive for the abscopal response and outcome. 
Further studies are warranted in this field to better 
understand and define the role of RT in combination or 
sequencing with ipilimumab treatment. 
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Purpose or Objective: The aim of this study was to analyze 
differences in radiological responses of melanoma brain 
metastases after Gamma Knife radiosurgery and their 
correlation with patient survival. 
 
Material and Methods: We retrospectively analyzed 78 
patients treated with Gamma Knife radiosurgery for 
melanoma brain metastases between 2009 and 2015 in the 
Radiosurgical centre (Saint-Petersburg, Russia) and subjected 
to follow-up MRI examinations. Patients receiving BRAF 
inhibitor therapy or ipilimumab were not included in the 
study. The study group consisted of 39 men and 39 women 
with a mean age of 52 years. The median KPS was 80 %. 
According to RPA, 14 patients were in Class I, 61 patients in 
Class II, and 3 patients in Class III. Most of the patients 
presented with multiple brain metastases (87 %). 
Radiosurgery was performed with Gamma Knife 4C and 
Perfection units; the mean dose delivered to the tumor 
margin was 20 Gy at 50 % isodose. After treatment, the 
patients underwent control MRI examination with standard 
protocols (2 mm T2 and 1 mm T1 with double contrast 
enhancement) at 8 weeks and at regular 3-month intervals 
thereafter. MR images were analyzed with Gamma Plan 
software. Volumetric measurements of metastases on pre- 
and post-treatment images were performed in order to 
determine different types of radiological response. We 
divided the patients into groups according to the type of 
radiological response and compared Kaplan-Meier survival 
curves in these groups with the long-rank test. 
 
Results: We found that patients with melanoma brain 
metastases had different radiological reactions to Gamma 
Knife radiosurgery. We distinguished several types of 
radiation response: sustained decrease in tumor volume, 
prolonged stabilization of tumor volume, transient increase in 
tumor volume due to intratumoral bleeding with subsequent 
decrease in tumor size, transient increase in tumor volume 
due to radiation-induced necrosis followed by tumor 
shrinkage. Statistical analysis revealed that a rapid decrease 
in tumor volume was associated with poor prognosis. Median 
overall survival of this group of patients was about two times 
less compared with patients whose radiation response 
developed slowly after the first 2 months of radiosurgery (p < 
0.0001). Stratification to RPA classes revealed that patients 
with a rapid response have poorer survival prognosis than 
those with a slow response in the corresponding RPA classes. 
 
Conclusion: Melanoma brain metastases showed different 
radiological responses to radiosurgery. Rapid shrinkage of 
brain metastases is associated with poor survival, which may 
indicate more aggressive biological behavior of this tumor 
subtype. Different radiation sensitivity of melanoma brain 
metastases to Gamma Knife radiosurgery may be associated 
with molecular characteristics of cell subpopulations, which 
determine biological tumor behavior and affect patient 
prognosis. 
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Purpose or Objective: Adult T-cell leukemia–lymphoma 
(ATLL) is a rare disease and a peripheral T-cell malignancy 
associated with human T-cell lymphotropic virus type I 
(HTLV-1) infection. ATLL treatment is based on 
subclassification, and intensive multidrug chemotherapy 
regimens are often used for aggressive subtypes. However, 
disease progression occurs in most of patients. There are only 
a few reports for the radiotherapy in patients with ATLL. 
Therefore, the role of radiotherapy for ATLL is not well 
investigated even for the palliation. The purpose of this study 
was to evaluate the efficacy and toxicity for the radiotherapy 
in patients with ATLL. 
 
Material and Methods: Between April 1983 to October 2013, 
44 patients with 205 ATLL tumor lesions were treated with 
radiotherapy at our institution. Sites of tumor lesions were as 
follows; 184 lesions were in the skin, 13 lesions in the lymph 
nodes, 6 lesions in the central nerves system, and 2 lesions in 
the bone. Acute type on ATLL subtypes was seen in 8 
patients, chronic type in 7 patients, lymphoma type in 10 
patients, smoldering type in 15 patients and others in 4 
patients. Median total dose of radiotherapy was 29Gy (range, 
2-60Gy), and the median fractionated dose was 3Gy (range, 
1-7Gy). For the skin tumor lesions, 45Gy in 15 fractions was 
selected in 33 lesions, 30Gy in10 fractions in 38 lesions, 28Gy 
in 4 fractions in 21 lesions and 20Gy in 5 fractions in 19 
lesions and others in 73 lesions. Only 4 of 44 patients were 
treated with total skin irradiation, and the remaining 40 
patients received conventional radiotherapy for local tumor. 
Efficacy and toxicity of the radiotherapy for ATLL were 
retrospectively evaluated, and the predictors of a long-term 
survival were analyzed. 
 
Results: The median follow-up period was 206 days. 
Objective tumor response rates were 98%. Four of 6 tumor 
lesions with stable disease or progressive disease on 
objective tumor response were associated with aggressive 
subtypes or tumor sites of the central nerves system. In-field 
recurrence after radiotherapy was recognized in 3 (2%) 
lesions. Two-year and 5-year overall survival rates were 76% 
and 44%, respectively. Median overall survival time in 
patients with indolent subtypes (chronic or smoldering type) 
of ATLL was 23 months, while that in patients with aggressive 
subtypes (acute or lymphoma type) was 6 months, and the 
difference was significant. Acute toxicities of Grade 2 
dermatitis were seen in 3 patients. Acute toxicity of Grades 
3–5 was not observed. Late toxicity of ≥Grade 2 was also not 
recognized. 
 
Conclusion: Radiotherapy for ATLL was mainly used for the 
skin lesion and well tolerated, and could achieve excellent 
local tumor control without inducing severe toxicity. 
Radiotherapy should be selected to improve the quality of 
life, and be incorporated into combined modality therapy for 
ATLL. 
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